In a multicenter study, the MICs of FK-037 for 90%o of the strains tested (MIC90s) were <1 ,ug/ml for members of the family Enterobacteriaceae other than Citrobacter freundii, Enterobacter spp., and Serratia marcescens. Activity against Pseudomonas aeruginosa was variable, with a MIC50 and a MIC,0 of 4 and 32 ,ug/ml, respectively. Relative to cefepime, however, FK-037 was less active against ceftazidime-resistant isolates of Enterobacter cloacae. The MIC,0 of FK-037 for methicillin-resistant staphylococci was >16 ,ug/ml.
FK-037 is a novel injectable oxime-type cephalosporin antibiotic with a 1-hydroxyethyl-5-aminopyrazole moiety at the three position (15) . Data presented in abstracts in 1991 and 1992 suggested that FK-037 was more active than currently available extended-spectrum cephalosporins against staphylococci, including methicillin-resistant strains (5, 12, 15) ; however, at four times its MIC, FK-037 reduced the number of CFU of methicillin-resistant Staphylococcus aureus by only 1 order of magnitude while vancomycin reduced the number of CFU by over 3 orders of magnitude in killing curve studies (1) . In studies by Neu et al. (14) , 16 ,ug of FK-037 per ml inhibited 50% of the S. aureus isolates tested with oxacillin MICs of >16 ,ug/ml. FK-037 has also been reported to have a broad spectrum of activity against gram-negative bacilli, including members of the family Enterobacteriaceae and Pseudomonas aeruginosa, and to be active against many ceftazidime-resistant isolates of Citrobacter spp., Enterobacter spp., and P. aeruginosa (2, 4-7, 11, 13, 16) . Fu et al. (2) , Neu et al. (14) , and Nishino et al. (15) have also demonstrated the activity of this compound against isolates of streptococci, including beta-hemolytic groups and Streptococcus pneumoniae, and Haemophilus influenzae. FK-037 has also been shown to be active against a variety of anaerobic bacteria other than the Bacteroides fragilis group (9) . Neu et al. (14) found that the MICs of FK-037 for 90% of the strains tested (MIC%0s) in the family Enterobacteriaceae were similar to those of cefepime and lower than those of ceftazidime and imipenem but that resistant mutants of Enterobacter cloacae, Citrobacter freundii, and S. aureus could be selected by daily transfer in the presence of FK-037.
The current study was undertaken to examine the activity of FK-037 in comparison with those of cefepime, ceftriaxone, ceftazidime, and cefuroxime against clinical isolates of gram-negative and gram-positive bacteria from five different medical centers. The five laboratories participating in the study were Table 2 . All of the cephalosporins tested were active against oxacillin-susceptible staphylococci; however, activity against oxacillin-resistant isolates was more variable, with MIC ranges extending from the lowest to above the highest concentrations tested. The MIC9,s of all of the cephalosporins tested against oxacillin-resistant S. aureus were greater than 16 ,ug/ml. The MIC90 of FK-037 against oxacillin-resistant S. epidermidis was 4 ,ug/ml, in contrast to 16 p,g of cefepime per ml and >16 jig/ml for the remaining cephalosporins. All of the cephalosporins tested were highly active against isolates of Streptococcus pyogenes and S. agalactiae.
In conclusion, our data confirm and extend findings previously reported by others regarding the high level of activity of FK-037 against Enterobacteriaceae species other than those characterized by Bush group I chromosomally mediated ,-lactamase, such as C. freundii, Enterobacter spp., and P. aeruginosa. In the latter regard, FK-037 has an activity in common with that of cefepime (3, 9) , which has been shown to be usually active against isolates of species that are resistant to cefoperazone, cefotaxime, and ceftazidime (1, 8, 10) . While FK-037 was highly active against gram-positive bacteria, its activity against oxacillin-resistant staphylococci was variable, undoubtedly reflecting variabilities in the degree of heterogeneous expression of resistance to oxacillin among the isolates tested.
